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José A. Pascual1,2
Chronic exposure to specific carcinogens present in secondhand smoke has been associated with 
different types of cancers. Hair is an ideal matrix to develop a proper biomarker as it absorbs substances 
in circulation and allows measuring their average concentration over long periods of time. A method 
was developed for the simultaneous quantification of nicotine, cotinine, NNN, NNK and NNAL in 
20 mg human hair samples. Concentrations were significantly different depending on the declared 
exposure. This study shows for the first time that NNK is present in hair samples from non-smokers in 
concentrations much higher than any other tobacco specific nitrosamine. NNN could also be detected 
in samples from the most exposed non-smokers while, as previously reported, NNAL was undetectable. 
NNK correlates well with nicotine and cotinine (rsp = 0.774 and rsp = 0.792 respectively, p < 0.001 in 
both cases). However, NNN concentrations did not correlate with any of the other analytes. Ratios 
between NNK and nicotine show variability with different concentrations of NNK present in samples 
with similar nicotine values. NNK has proven to be the best marker of tobacco specific nitrosamines 
in hair. Monitoring NNK may provide a good estimation of cancer risk associated with exposure to 
secondhand smoke.
Exposure to secondhand tobacco smoke (SHS) increases the risk of respiratory and cardiovascular diseases1,2 
and it is classified as Group1 carcinogen in humans by the International Agency for Research on Cancer (IARC)1. 
Tobacco specific nitrosamines (TSNAs) and particularly N′ -nitrosonornicotine (NNN) and 4-(methylnitrosami-
no)-1-(3-pyridyl)-1-butanone (NNK), are also classified as Group 1 carcinogens in humans3 (Fig. 1). While NNN 
is strongly associated with esophageal cancer risk in smokers4–7, NNK and its main metabolite 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone (NNAL) are involved in lung, pancreas and other sorts of cancers4,5,8–13.
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Moreover, NNN and NNK are the most prevalent strong carcinogens in unburned tobacco products4. They are 
present in mainstream and secondhand smoke14,15 but also in thirdhand smoke16,17. Whereas airborne nicotine 
concentrations decrease over time, NNK continues being generated in smoke even hours after it was emitted18. 
Consequently, second and thirdhand smoke may lead to a significant unnoticed uptake of NNK.
Monitoring chronic exposure to tobacco specific carcinogens (i.e. TSNAs), particularly in non-smokers, is 
very relevant in evaluating the impact on public health of the implementation of smoke-free laws. Biomarkers of 
tobacco smoke exposure are essential to study the metabolic fate of tobacco products and their potential health 
risk. Nicotine and its main metabolites cotinine, and trans-3′ -hydroxycotinine have been extensively used as spe-
cific markers in smokers and non-smokers exposed to SHS19–26. TSNAs occur in much lower concentrations and 
their detection is challenging27–29. Exposure to TSNAs has been mainly approached by quantifying total NNAL 
(free, plus N and O-glucuronides) in urine of smokers and non-smokers, although serum has also been used30–35. 
The detection of NNAL in urine samples from non-smokers has strengthened the argument that passive smoking 
is linked with lung cancer5. NNAL/cotinine ratios are significantly higher in samples from non-smokers than 
from smokers, suggesting that involuntary or passive smoking, i.e. exposure to TSNAs in second and third-hand 
smoke, might be underestimated by using cotinine as biomarker of exposure28,36,37. The analysis of urine, blood 
or saliva gives a good indication of the exposure in the last few days, considering the half-life of the analyte and 
the nature of the biological matrix9,30. Conversely, analysis of keratinic matrices, such as hair and nails, has some 
advantages over those biological fluids. Circulating drugs are embedded in hair or nails as they grow. The adsorp-
tion mechanisms are not fully understood but, in hair, there seems to be a significant role played by melanines 
with basic and less polar compounds being selectively enriched20,22,38. Nicotine, for example, is found in hair in 
concentrations 10–100 times higher than its main metabolite cotinine20. The absence of metabolism in these solid 
matrices precludes degradation of the analytes and, as hair grows 1 cm per month on average, a segmental anal-
ysis allows ‘recording’ of tobacco cumulative exposure over long periods of time39,40. Exposure to SHS measured 
through hair analysis is therefore less affected by the daily variability allowing a more robust comparison. This is 
particularly relevant when dealing with a non-smoker population, irregularly exposed to SHS27.
Figure 1. Chromatograms of the analysis of hair samples from a representative exposed non-smoker 
(living with at least one smoker) and a non-smoker living in a smoke-free home. Chromatograms are given 
for the individual analytes (nicotine, cotinine, NNN, NNK and NNAL) and their respective deuterated internal 
standards (I.S.). NNK, the most abundant TSNA in hair samples, is highlighted.
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NNAL has been detected in toenails and hair from regular smokers (i.e. more than 10 cigarettes per day) in 
concentrations ranging 0.04–4 pg/mg and 0.27–0.67 pg/mg respectively41,42. However it has been undetectable in 
samples from non-smokers41. NNN has also been found in toenails from smokers and non-smokers in concen-
trations below 5 pg/mg43.
The objective of this project was the analysis of different tobacco specific biomarkers, including particularly 
TSNAs, in hair samples from non-smokers in an attempt to find the best candidate. Considering the behaviour 
of nicotine and cotinine, the hypothesis was that NNK might be the most suitable hair biomarker of cumulative 
exposure to TSNAs.
Results
A procedure was developed for the simultaneous quantification of nicotine, cotinine, NNN, NNK and NNAL in 
hair samples. Lower limits of quantification (LLOQs) were set at 25, 2.5, 0.25, 0.10 and 0.063 pg/mg respectively, 
using 20 mg of hair. The amount of sample available varies a lot depending on the subject, therefore the use of 
lower or higher amounts of matrix was tested and validated as not affecting precision and accuracy. However, 
there is an obvious impact on the limit of quantification reached for any particular sample. The analysis of sam-
ple amounts between 5 and 50 mg did not produce any significant differences in quantification other than the 
achievable LOQs.
Deuterated internal standards (I.S.) were used for all analytes. Linearity was proven to be good for the cali-
bration ranges tested with coefficients of determination (r2) being above 0.99 in all cases. Confidence intervals 
(IC95%) of the regression parameters of the calibration curves prepared in matrix and in absence of matrix 
showed not to be significantly different (p < 0.05). Calibrators prepared in matrix complied with the accuracy 
requirements when back-calculated using curves prepared in absence of matrix. Precision, expressed as the 
coefficient of variation, and accuracy, as percent of error, was determined by quantifying five replicates of con-
trol samples prepared in hair at low, medium and high levels through the calibration range. Typical values were 
well below 10%. Only cotinine and NNAL at the lowest concentration gave a higher but still acceptable varia-
tion (Table 1). Extraction recoveries were found to be appropriate ranging 65–97% depending on the analyte. 
However, as shown in similar methods, the matrix effect significantly influences the overall process efficiency, but 
those effects proved to be properly compensated by the deuterated internal standards used for quantification pur-
poses. N-Glucuronides of the deuterated analogues of nicotine, cotinine and NNAL (those commercially avail-
able) were also taken through the procedure and, as previously reported43–45 it was proven that N-glucuronides 
of those compounds are completely hydrolyzed under the basic incubation conditions used to digest hair. The 
O-glucuronide of NNAL was not completely hydrolysed, although previous publications suggest that it is not even 
present in hair42. Therefore, it can be stated that the results account for the total amount of the analytes (free plus 
glucuronides). Individual standards of nicotine, cotinine, 3′ -hydroxycotinine and nornicotine (1 μ g each) were 
taken through the analytical procedure and NNK production in measurable amounts was discarded. The identity 
of both NNK and NNN was confirmed following the chromatographic and MS criteria of the latest technical 
document issued by the World Anti Doping Agency (TD2015IDCR)46.
Hair of non-smokers (N = 48) were analysed for nicotine, cotinine, NNN, NNK and its main metabolite 
NNAL. From the 48 volunteers recruited, 24 declared living with at least one smoker while 24 non-smokers lived 
in smoke-free homes. However, all were asked about other sources of potential exposure (i.e. at work, transporta-
tion, leisure time). Only 6 declared not being exposed at any time. Exposure at home resulted in the most signifi-
cant source, as measured by salivary cotinine values19.
Nicotine and cotinine concentrations spanned over a wide range with medians of 1,160 pg/mg and 37 pg/mg 
respectively and correlated well (Spearman’s coeff . rsp = 0.779, p < 0.001). Table 2 gives the results segregated 
by declared exposure the declaration of being exposed at home (living with a smoker or in a smoke-free home). 
The analysis of TSNAs showed undetectable or not quantifiable concentrations of NNAL in all samples. However 
NNK, its precursor and potent carcinogen, was detected in concentrations ranging 0.1–7.8 pg/mg. NNN could 
also be detected in samples from some of the most exposed individuals. Figure 1 shows representative chromato-
grams of the analysis of a self-declared exposed individual and a person living in a smoke-free home.
NNK correlates very significantly with nicotine concentrations (Spearman’s coeff . rsp = 0.774, p < 0.001) and 
also with cotinine (Pearson’s coeff . r = 0.792, p < 0.001) (Fig. 2). Interestingly, no correlation was found between 
NNN and any of the other analytes, although probably the total number of samples for which a concentration 
of NNN could be measured does not allow obtaining definitive conclusions. The NNK/nicotine ratio was found 
to show a wide variation, even with this good correlation. Several samples with similar nicotine concentrations 
showed very different NNK values (See Fig. 2a). The overall median of the ratio NNK /nicotine was 0.49·10−3 
QC
Nicotine Cotinine NNN NNK NNAL
Conc.  
(pg/mg) %CV %err
Conc.  
(pg/mg) %CV %err
Conc.  
(pg/mg) %CV %err
Conc. 
(pg/mg) %CV %err
Conc. 
(pg/mg) %CV %err
Low 30 7.0 11 3 19 − 13 0.3 4.1 − 0.8 0.13 9.0 6.6 0.075 2.9 19
Medium 750 0.6 8.9 750 9.2 0.5 0.75 3.6 − 0.6 0.75 3.6 − 3.2 0.15 2.5 − 1.4
High 2,000 1.9 12 2,000 5.7 8.7 2.0 2.3 0.7 1.7 4.9 8.4 0.35 2.1 0.6
Table 1. Precision (%CV) and accuracy (%err) intra-assay values obtained for the quality control samples 
(QC) analysed in parallel with the “non-smoker” calibration curves.
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with an interquartile range 0.35·10−3–0.64·10−3. When the calculation is segregated by exposed or not exposed (at 
home) values show a slight trend towards higher values of the ratio for exposed individuals (Table 2).
Discussion
The evaluation of health risks linked with the exposure to SHS, and particularly those associated with different 
types of cancer, has led research efforts to the study of TSNAs. With the implementation of smoke-free laws in 
many countries, active efforts have been directed towards monitoring exposure in non-smokers. The analysis 
of hair samples gives a good estimate of averaged exposure over a period of more than one month. Nicotine 
and cotinine concentrations were found to be consistent with those already reported in similar populations20. 
Exposure to tobacco specific carcinogens (i.e. TSNAs) has been regularly measured by quantifying total NNAL 
in urine samples, although it is known to represent less than 20% of the NNK dose intake in smokeless tobacco 
users47. However, NNAL has been shown in low concentrations in toenails or hair from smokers, and it has shown 
to be undetectable in samples from non-smokers41,42. NNN had been detected in toenails of non-smokers with a 
mean concentration of 0.062 pg/mg and it correlated with cotinine concentrations43. This study shows for the first 
time that NNK is the most abundant TSNA present in hair and it can be detected in samples from non-smokers 
in concentrations much higher than any other nitrosamine. The analysis of other biological matrices like urine 
shows that NNK is absent after extensive metabolism and NNAL is chosen as the main NNK metabolic marker. 
However, the situation in hair has proven to be completely different. Analogous to what happens with nicotine 
vs cotinine, the concentrations of the precursor NNK showed to be much higher than those of its metabolic ana-
logue NNAL which is consistently undetectable in samples from non-smokers. Concentrations of NNK in sam-
ples from non-smokers were up to 7.8 pg/mg, with an overall mean of 1.7 pg/mg. The availability of low amounts 
of hair for some subjects (e.g. down to 2.4 mg) and the real lack of exposure to SHS of some others, accounts for 
those samples without quantifiable amounts of NNK. NNAL was always below the limit of quantification (0.06 pg/
mg). Conversely, reported concentrations of NNAL in hair samples from heavy smokers never went above 0.7 pg/
mg, while in toenails mean concentrations were 0.41 pg/mg. Sample amounts between 50 and 150 mg were 
used41,42. Nicotine, cotinine and NNK values were significantly higher in those subjects declaring being exposed. 
The number of samples where NNN could be quantified precluded this evaluation, although the values showed 
a similar trend. NNK concentrations correlate very significantly with nicotine and cotinine. When volunteers 
Group Nicotine Cotinine NNN NNK NNAL
Exposed at home (N = 24)
 Median (IQR) [pg/mg] 2,040 (1,200; 4,650) 49 (26; 106) 0.54 (0.29; 0.60) 1.3 (0.92; 2.7) –
 Mean (SE) [pg/mg] 3,320 (664) 74 (14) 0.54 (0.067) 2.1 (0.40) –
 N (quantifiable) 24 21 7 15 0
Non-exposed at home (N = 24)
 Median (IQR) [pg/mg] 623 (221; 1,160) 26 (16; 43) 0.41 (− ) 0.74 (0.31; 1.1) –
 Mean (SE) [pg/mg] 1,330 (527) 95 (55) 0.41 (0.027) 1. 1 (0.34) –
 N (quantifiable) 24 16 2 11 0
p (2-tailed) (Mann-Whitney) 0.001 0.030 – 0.018 –
Table 2. Concentration of the analytes found in hair samples from 48 non-smokers segregated by their self-
declaration of living with at least one smoker or in a smoke-free home. Median (interquartile range (IQR)) 
and mean (standard error, SE) are given for each group.
Figure 2. Plots showing the correlation between NNK and nicotine (a) or cotinine (b) found in hair samples 
from 48 non-smokers participating in the study.
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were grouped by their degree of exposure to SHS19, significant differences were found, showing the goodness of 
the biomarkers. Interestingly, NNN could also be quantified in samples from the non-smokers most exposed to 
SHS, but the concentrations did not correlate with any of the other analytes. No correlation was found between 
salivary cotinine concentrations19 and hair cotinine (Pearson’s coeff . r = 0.182, p = 0.289), NNK (Pearson’s 
coeff . r = 0.102, p = 0.621) or NNN (Pearson’s coeff . r = − 0.122, p = 0.754). However, a weak correlation could 
be found between salivary cotinine and hair nicotine (Pearson’s coeff . r = 0.344, p = 0.019). The mechanism of 
incorporation of the substance into hair and probably the whole metabolic fate of NNN may play an important 
role. NNAL/cotinine ratios in urine samples have shown differences between active and passive smokers28,36,37. 
A NNK/nicotine ratio in hair is a very promising new marker and its values should be compared with those 
obtained from smokers in order to confirm if a significant increase in the relative NNK exposure with respect to 
nicotine could be detected in passive smokers.
The method developed has proven to be a reliable tool for analyzing nicotine, cotinine, NNN, NNK, NNAL, 
in human hair samples. Considering the important differences between individual hair samples (colour, cosmetic 
treatments, age of the donors, etc.) and the unavoidable varying matrix composition, it became obvious that the 
use of calibration curves in a particular hair sample did not solve those problems. Besides, a reliable source of 
real blank hair samples is not easy to find, bearing in mind the ubiquity of tobacco smoke in our environment. 
Accordingly, we followed a validation strategy48 where calibration curves are prepared both in matrix and in 
the absence of matrix (taking the standards through the whole sample preparation and analysis process as real 
samples) but QC samples are prepared in matrix and quantified against both curves. Limits of quantification are 
comparable to previous publications. LOQs depend mainly on the amount of sample available and to a minor 
extent on the individual matrix effect, as it might not equally affect signal and noise. The method was developed 
using 20 mg of hair only, considering that the amount of sample is frequently a limiting factor.
Nicotine in hair is a very good biomarker of long-term exposure to SHS and it is the easiest to detect48. 
However, these results show that NNK exposure can be reliably measured and its ratio to nicotine might vary 
from individual to individual. Therefore, monitoring NNK in hair should be a much better marker of individual 
carcinogenic risk, especially among non-smoker population, irregularly exposed to SHS.
This study has several limitations that is worth mentioning. As in any hair analysis, the hair composition (e.g. 
colour of the hair, cosmetic treatments, etc.) might have an impact on the final concentrations found. The number 
of samples analysed has to be increased in order to better correlate exposure or smoking habits with these TSNAs. 
In particular, samples from recreational and heavy smokers need to be analysed for this reason.
Methods
Safety Hazards. NNK, NNN and NNAL are carcinogenics and mutagenics and should be handled with 
extreme care.
Chemicals. (− )-Nicotine and (− )-cotinine 1.0 mg/mL standard solutions in methanol as well as HPLC 
grade formic acid were purchased from Fluka-Sigma-Aldrich (Madrid, Spain). ( ± )-nicotine-d4 (2,4,5,6-tetrad
eutero-3-(1-methylpyrrolidin-2-yl)-pyridine) 100 μ g/mL solution in acetonitrile and ( ± )-cotinine-d3 (5-(3-pyr
idinyl)-1-trideuterometyl-2-pyrrolidinone) 1.0 mg/mL in methanol, were purchased from Cerilliant Corp 
(Round Rock, Texas, USA). (± )-N′ -nitroso-nornicotine (NNN), (± )-NNN-d4 (2,4,5,6-tetradeutero-(5-(1-nitro-
so-2-pyrrolidinyl))-pyridine), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), NNK-d4 (4-(methylni-
trosamino)-1-(2,4,5,6-tetradeutero-3-pyridyl)-1-butanone, (± )-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) and (± )-NNAL-d3 (4-(trideuteromethyl-nitrosamino)-1-(3-pyridyl)-1-butanol were purchased from 
Toronto Research Chemicals (Ontario, Canada). HPLC grade methanol, acetonitrile and 2-propanol, as well as 
analytical grade sodium hydroxide, potassium chloride, 25% ammonia solution and 37% fuming hydrochloric 
acid were obtained from Merck Millipore (Darmstadt, Germany). HPLC grade dichloromethane was purchased 
from Scharlau (Barcelona, Spain). Ultrapure water was produced using a Millipore Milli-Q water purification 
system. Nitrogen was obtained from a central high flow permanent supply using a liquid nitrogen bulk tank 
(99.5%, Praxair, Spain). Sample processing tubes were KIMAX 16 × 125 mm screw cap glass borosilicate tubes 
from Kimble Chase (Queretaro, Mexico).
Subjects. 48 non-smokers of both sexes were recruited from a cross-sectional study to evaluate the impact 
of the Spanish smoke-free law 28/2005 on the exposure to secondhand smoke of the adult population of the 
city of Barcelona, Spain19,49. The research and ethics committee of Bellvitge University Hospital (L’Hospitalet 
de Llobregat, Barcelona, Spain) approved the study protocol, and all participants signed an informed consent. 
The study was performed in accordance with the Declaration of Helsinki ethical principles for medical research 
involving human subjects. Data was treated in compliance with the Spanish Law of Personal Data Protection (Law 
15/1999). Participants were asked if they were exposed to SHS. Hair samples, cut close to the scalp, were collected 
from the vertex posterior where possible. They were kept in individual envelopes at room temperature with both 
ends (proximal and distal) identified.
Sample preparation. The segment of hair to be analysed (i.e. 1.5 cm of the proximal end, close to the scalp) 
was first washed three times with CH2Cl2 by sonication for 10 min38. After drying at a temperature below 40°C, 
samples were put in flat bottomed plastic tubes (50 × 16 mm), finely cut with scissors and kept at room tempera-
ture until analysis. The sample preparation procedure is similar to other previously published with some modifi-
cations50,51. An amount of ca. 20 mg was weighed in a sample processing tube and 50 μ L of internal standard (IS) 
solution (10 ng nicotine-d4, 2 ng cotinine-d3, 20 pg NNN-d4, 20 pg NNK-d4 and 4 pg NNAL-d3) were added. The 
mixture was digested for 30 min at 80 °C in 1 mL 1 M NaOH, 2 M KCl aqueous solution and then allowed to cool 
to room temperature38. The resulting digested samples were extracted with 5mL CH2Cl2 and 5 mL CH2Cl2:iPrOH 
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(75:25) consecutively by rocking mixing for 15 min at a frequency of 50 min−1 and centrifuging at 2,026 g for 
10 min. The combined organic phases were back-extracted with 1 mL 0.5 M HCl in another sample processing 
tube. The aqueous phase was made alkaline with 1 mL 1M NaOH, 2M KCl and extracted again with 4 mL CH2Cl2 
and 4 mL CH2Cl2:iPrOH (75:25) consecutively. The organic phases were combined and, after addition of 100 μ L 
25 mM HCl in MeOH, concentrated to dryness under a gentle N2 stream. Dry extracts were re-dissolved in 100 μ L 
ACN/MeOH (95:5) and transferred to an injection vial with a small volume insert and kept in the instrument 
autosampler at 4 °C. The suitability of the use of calibration curves in the absence of matrix was tested during 
method validation. Calibration curves and quality controls (low medium and high) were prepared in 20 mg blank 
hair and back-calculated using the calibration curve prepared in absence of matrix to test for the adequacy of 
the method. Precision and accuracy of the quantifications were required to be within ± 15% along the whole 
calibration range (including medium and high QCs) and within ± 20% for the LLOQ (and low QC). The impact 
of the amount of hair analysed on the quantification was tested by homogenizing a hair sample known to contain 
detectable concentrations of the analytes, and analyzing amounts of 5, 10, 20 and 50 mg. Calibration curves were 
prepared covering a double range during method validation, one for non-smoker samples and another for poten-
tially high concentrations. Ranges were 25–2,500 pg/mg (or up to 500 ng/mg) for nicotine, 2.5–2,500 pg/mg (or 
up to 500 ng/mg) for cotinine, 0.25–2.5 pg/mg (or up to 10 pg/mg) for NNN, 0.10–2.0 pg/mg (or up to 50 pg/mg 
for NNK) and 0.063–0.40 pg/mg (or up to 6.3 pg/mg) for NNAL.
Liquid chromatography-tandem mass spectrometry. Instrumental analyses were performed on an 
Agilent Technologies LC 1290 Infinity HPLC system connected to an Agilent 6490 triple quadrupole mass spec-
trometer, through an iFunnel ionization source working in positive ionization mode. The chromatographic sepa-
ration was achieved using a normal phase chromatographic column Cogent Diamond Hydride column 100 mm 
long, 2.1 mm I.D. 120 Å pore, 4.0 μ m particle size. The auto-sampler tray temperature was kept at 4 °C. The needle 
of the injector was externally rinsed with MeOH for 15 seconds prior to each injection. The mobile phase passed 
through the needle for the whole duration of the chromatographic run. The column temperature was kept at 35 °C 
and the volume injected was 10 μ L.
Chromatographic separation was achieved using a binary gradient of (A) 100 mM aqueous ammonium for-
mate solution taken to pH 3 with formic acid and (B) acetonitrile, at a flow rate of 0.6 mL/min. The gradient 
was: isocratic at 1% A during 1.5 min; increased linearly up to 5% A in 0.5 min; increased linearly up to 50% A 
in 0.5 min; kept at 50% A for 1.5 min; return to initial conditions in 1 min. Total chromatographic time 5 min. 
Acquisition was performed in multiple reaction monitoring (MRM) mode. iFunnel source conditions were as 
follows: capillary voltage (positive), 3000 V; desolvation gas temperature, 100 °C; drying gas flow, 12 L/min; nebu-
lizer, 35 psi; sheath gas heater, 275 °C; sheath gas flow, 12 L/min; charging voltage, 750 V. High-purity nitrogen 
(99,999%, Abello-Linde, Spain) was used as collision gas. As nebulizer and drying gas, nitrogen was obtained 
from a central high flow permanent supply using a liquid nitrogen bulk tank (99.5%, Praxair, Spain).
MS/MS parameters were optimized by injecting 10 μ L of 10 ng/mL individual standard solutions in acetoni-
trile. Fragmentor voltage at 380 V, cell accelerator voltage at 4 V and dwell time 58 ms were used in all cases. 
Collision energy was optimized for each compound and fragments being between 9 and 49 V for all transitions. 
The MRM transitions for quantification and identification were respectively: m/z 163 to 130 and 117 for nico-
tine and m/z 167 to 134 and 121 for nicotine-d4; m/z 177 to 80 and 98 for cotinine and m/z 180 to 80 and 53 for 
cotinine-d3; m/z 178 to 148 and 119 for NNN and m/z 182 to 152 and 124 for NNN-d4; m/z 208 to 122 and 79 
for NNK and m/z 212 to 126 and 83 for NNK-d4; m/z 210 to 93 and 108 for NNAL and m/z 213 to 93 and 108 
for NNAL-d3. All data were acquired and processed using MassHunter Quantitative Analysis v B.06.00 software.
Statistical analyses. We described the concentrations of biomarkers using median (interquartile range 
(IQR)) and mean (standard error, SE) according to the self-reporting SHS exposure at home. We compared the 
concentrations of biomarkers according to the self-reporting SHS exposure at home using the Mann Whitney 
U-test for two independent samples. Given the skewed distribution of biomarkers, we used Spearman’s rank cor-
relation coefficient (rsp) to assess the association between biomarkers.
For all analyses, we used PASW Statistics 18, Release 18.0.0 2009 (SPSS, Inc., Chicago, IL).”
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